AR043138A1 - Derivados de acido prostanoico de 10, 10-dialquilo como agentes para disminuir la presion intraocular - Google Patents
Derivados de acido prostanoico de 10, 10-dialquilo como agentes para disminuir la presion intraocularInfo
- Publication number
- AR043138A1 AR043138A1 ARP040100405A ARP040100405A AR043138A1 AR 043138 A1 AR043138 A1 AR 043138A1 AR P040100405 A ARP040100405 A AR P040100405A AR P040100405 A ARP040100405 A AR P040100405A AR 043138 A1 AR043138 A1 AR 043138A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- halogen
- indicates
- heteroaryloxy
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000004410 intraocular pressure Effects 0.000 title 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Chemical class 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract 2
- -1 or CO2R Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 1
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical class [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporciona un método para tratar la hipertensión ocular o glaucoma, que comprende administrar a un mamífero que padezca hipertensión, ocular o glaucoma, una cantidad terapéuticamente efectiva de un compuesto representado por la fórmula general (1), en donde la línea de guiones indica la presencia o ausencia de un enlace, la parte sombreada indica la configuración alfa (abajo), el triángulo de color uniforme sin líneas, indica la configuración beta (arriba); B es un enlace covalente único, doble o triple; n es 0-6; X es CH2, S u O; Y es cualquier sal farmacéuticamente aceptable de CO2H, o CO2R, CONR2. CONHCH2CH2OH, CON(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONNR2, o fórmula (2), R es H, alquilo C1-6 o alquenilo C2-6; R2 y R3 son alquilo C1-6, lineal, que pueden ser iguales o diferentes, y pueden estar ligados entre sí de manera de formar un anillo que incorpora el carbono al que se encuentran normalmente unidos; R4 es hidrógeno, R, C(=O)R, o cualquier grupo que sea fácilmente eliminado bajo condiciones fisiológicas, de manera que R4 sea efectivamente hidrógeno; R5 es hidrógeno o R; R6 es hidrógeno; un hidroarbono lineal o ramificado que contiene entre 1 y 8 átomos de carbono, que puede contener uno o más dobles o triples enlaces, u oxígeno o derivados de halógeno de dicho hidrocarbono, donde los átomos de 1-3 o de hidrógeno pueden sustituirse por O o por un halógeno; o ariloxi, heteroariloxi, cicloalquiloxi C3-8, cicloalquilo C3-8, arilo C6-10, o heteroarilo C3-10, donde uno o más carbonos se sustituyen con N, O, o S; y que pueden contener uno o más sustituyentes seleccionados del grupo que comprende halógeno, trihalometilo, ciano, nitro, amino, hidroxi, arilo C6-10, heteroarilo C3-10, ariloxi, heteroariloxi, alquilo C1-6, OR, SR, y SO2R.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/365,369 US6875787B2 (en) | 2003-02-11 | 2003-02-11 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043138A1 true AR043138A1 (es) | 2005-07-20 |
Family
ID=32824631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100405A AR043138A1 (es) | 2003-02-11 | 2004-02-10 | Derivados de acido prostanoico de 10, 10-dialquilo como agentes para disminuir la presion intraocular |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6875787B2 (es) |
| EP (2) | EP2263674B1 (es) |
| CN (3) | CN102050811A (es) |
| AR (1) | AR043138A1 (es) |
| CY (1) | CY1113138T1 (es) |
| DK (2) | DK1608309T3 (es) |
| ES (2) | ES2391393T3 (es) |
| HK (1) | HK1086191A1 (es) |
| IL (1) | IL170052A (es) |
| PT (1) | PT1608309E (es) |
| SI (1) | SI1608309T1 (es) |
| TW (1) | TWI329631B (es) |
| ZA (1) | ZA200505728B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
| US7101906B2 (en) | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| TWI386208B (zh) * | 2005-04-18 | 2013-02-21 | Allergan Inc | 治療性的經取代環戊酮 |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| US20110052695A1 (en) * | 2009-04-20 | 2011-03-03 | Allergan, Inc. | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| WO2010123946A2 (en) | 2009-04-20 | 2010-10-28 | Allergan, Inc. | Silk fibroin hydrogels and uses thereof |
| NZ607306A (en) | 2010-07-30 | 2015-03-27 | Allergan Inc | Compounds and methods for skin repair |
| KR20140003395A (ko) | 2010-08-17 | 2014-01-09 | 알러간, 인코포레이티드 | 각막 혼탁 치료용 ep2 또는 ep4 항진제들 |
| WO2012024072A1 (en) * | 2010-08-19 | 2012-02-23 | Allergan, Inc. | Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition |
| US8741281B2 (en) * | 2010-08-19 | 2014-06-03 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8697057B2 (en) * | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120142684A1 (en) | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| CA2832589A1 (en) | 2011-04-07 | 2012-10-11 | Allergan, Inc. | Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| CN106062303B (zh) | 2014-03-07 | 2019-05-14 | 德国德力能有限公司 | 用于将引爆器定位在射孔枪组件内的装置和方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117014A (en) * | 1976-01-09 | 1978-09-26 | Abbott Laboratories | Prostaglandin derivatives |
| JPS59101458A (ja) * | 1982-12-01 | 1984-06-12 | Nippon Iyakuhin Kogyo Kk | 新規なチアプロスタグランジン誘導体及びその製法 |
| JPS632972A (ja) * | 1986-06-20 | 1988-01-07 | Nippon Iyakuhin Kogyo Kk | 新規プロスタグランジンｅ↓１誘導体及びその製法 |
| US6187813B1 (en) * | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| AU635294B2 (en) * | 1989-07-27 | 1993-03-18 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| CA2020254A1 (en) * | 1989-07-27 | 1991-01-28 | Ming F. Chan | Intraocular pressure reducing 9, 15-diacyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| US6034413A (en) * | 1997-02-27 | 2000-03-07 | Texas Instruments Incorporated | High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity |
| DE10057158C1 (de) * | 2000-11-16 | 2002-03-28 | Asglawo Gmbh Stoffe Zum Daemme | Lagerungsmatte für die Lagerung eines Abgaskatalysators |
| US6531504B2 (en) * | 2001-05-17 | 2003-03-11 | Allergan, Inc. | Prostanoic acid derivatives as agents for lowering intraocular pressure |
| NZ532519A (en) * | 2001-11-05 | 2006-11-30 | Allergan Inc | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US7175476B2 (en) * | 2005-01-11 | 2007-02-13 | Daeun Electronics Co., Ltd. | Crosstalk canceling pattern for high-speed communications and modular jack having the same |
-
2003
- 2003-02-11 US US10/365,369 patent/US6875787B2/en not_active Expired - Lifetime
-
2004
- 2004-02-04 US US10/772,720 patent/US20040235958A1/en not_active Abandoned
- 2004-02-06 EP EP10178294.4A patent/EP2263674B1/en not_active Expired - Lifetime
- 2004-02-06 DK DK04709028.7T patent/DK1608309T3/da active
- 2004-02-06 EP EP14177792.0A patent/EP2803358B1/en not_active Expired - Lifetime
- 2004-02-06 CN CN2010105303996A patent/CN102050811A/zh active Pending
- 2004-02-06 DK DK10178294.4T patent/DK2263674T3/da active
- 2004-02-06 CN CNA2004800026773A patent/CN1758915A/zh active Pending
- 2004-02-06 PT PT04709028T patent/PT1608309E/pt unknown
- 2004-02-06 CN CN201010530469.8A patent/CN102050812B/zh not_active Expired - Fee Related
- 2004-02-06 SI SI200431931T patent/SI1608309T1/sl unknown
- 2004-02-06 ES ES04709028T patent/ES2391393T3/es not_active Expired - Lifetime
- 2004-02-06 ES ES10178294.4T patent/ES2515217T3/es not_active Expired - Lifetime
- 2004-02-10 AR ARP040100405A patent/AR043138A1/es not_active Application Discontinuation
- 2004-02-11 TW TW093103178A patent/TWI329631B/zh not_active IP Right Cessation
-
2005
- 2005-07-18 ZA ZA200505728A patent/ZA200505728B/xx unknown
- 2005-08-02 IL IL170052A patent/IL170052A/en active IP Right Grant
-
2006
- 2006-06-02 HK HK06106364.9A patent/HK1086191A1/xx not_active IP Right Cessation
-
2012
- 2012-09-25 CY CY20121100873T patent/CY1113138T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040157901A1 (en) | 2004-08-12 |
| HK1086191A1 (en) | 2006-09-15 |
| DK2263674T3 (da) | 2014-10-27 |
| EP2803358B1 (en) | 2017-05-03 |
| ES2515217T3 (es) | 2014-10-29 |
| TW200512184A (en) | 2005-04-01 |
| DK1608309T3 (da) | 2012-09-03 |
| US6875787B2 (en) | 2005-04-05 |
| EP2803358A1 (en) | 2014-11-19 |
| TWI329631B (en) | 2010-09-01 |
| ES2391393T3 (es) | 2012-11-23 |
| CY1113138T1 (el) | 2016-04-13 |
| EP2263674B1 (en) | 2014-07-23 |
| CN102050812A (zh) | 2011-05-11 |
| IL170052A (en) | 2011-10-31 |
| EP2263674A1 (en) | 2010-12-22 |
| CN1758915A (zh) | 2006-04-12 |
| PT1608309E (pt) | 2012-10-18 |
| US20040235958A1 (en) | 2004-11-25 |
| SI1608309T1 (sl) | 2012-11-30 |
| ZA200505728B (en) | 2006-04-26 |
| CN102050812B (zh) | 2015-02-18 |
| CN102050811A (zh) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043138A1 (es) | Derivados de acido prostanoico de 10, 10-dialquilo como agentes para disminuir la presion intraocular | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR035716A1 (es) | Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos | |
| ES2188961T3 (es) | Derivados de piperidina 1,4-disustituidos fluorados. | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| HUE027357T2 (en) | Prostaglandin nitrooxy derivatives | |
| UY26276A1 (es) | 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164 | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| ES2243933T3 (es) | Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii. | |
| AR043355A1 (es) | Compuestos derivados de amida, preparacion de medicamentos que los contienen para el tratamiento y prevencion de trastornos asociados con glucocorticoides | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| NO20053715L (no) | 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk | |
| AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
| CO4950557A1 (es) | Compuestos y metodos | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| PE20061295A1 (es) | Derivados de acetileno | |
| AR045856A1 (es) | Derivados de tropano sustituidos con imidazopiridinas,procedimiento de preparacion,composiciones farmaceuticas que los contienen y usos, | |
| PE20070120A1 (es) | Derivados de prostaglandina | |
| PE53097A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos | |
| AR034350A1 (es) | Indazoles e indoles fusionados, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento para el tratamiento de glaucoma | |
| NO923798L (no) | Fremgangsmaate for fremstilling og anvendelse av nye acylaler av imidazol-5-karboksylsyrederivater | |
| AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
| FI93451B (fi) | Menetelmä terapeuttisesti käyttökelpoisten /(3aS-cis)-1,2,3,3a,8,8a-heksahydropyrrolo/2,3-b/indol-5-yyli/aminokarbonyyli/karbamaattijohdannaisten valmistamiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |